Home > Publications Database > Subjective cognitive decline in individuals with isolated REM sleep behavior disorder. > print

001     281634
005     20251103102758.0
024 7 _ |a 10.1038/s41531-025-01161-2
|2 doi
024 7 _ |a pmid:41057346
|2 pmid
037 _ _ |a DZNE-2025-01157
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ophey, Anja
|b 0
245 _ _ |a Subjective cognitive decline in individuals with isolated REM sleep behavior disorder.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762161330_20025
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Subjective cognitive decline (SCD) may constitute an early marker of mild cognitive impairment (MCI) in individuals with isolated REM sleep behavior disorder (iRBD). In this cross-sectional study, 80 individuals with iRBD were classified into iRBD with MCI (RBD.MCI), with SCD (RBD.SCD+), and without both (RBD.SCD-) based on neuropsychological testing and the Multi-SubCoDE questionnaire. The prevalence of SCD in iRBD was 36.3%, with predominance of the amnestic multi-domain SCD profile. RBD.SCD+ reported more severe depressive symptoms than RBD.SCD- and showed lower cognitive performance than RBD.SCD- in global cognition and attention & working memory. Magnetic resonance imaging analyses revealed lower grey matter volume in the left superior frontal gyrus for RBD.SCD+ than RBD.SCD-, which was associated with increased SCD-severity and lower global cognition. SCD without MCI in iRBD is associated with subtle cognitive deficits and structural brain changes. The prognostic value of SCD in iRBD should be further determined in longitudinal studies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Röttgen, Sinah
|b 1
700 1 _ |a Doppler, Christopher E J
|b 2
700 1 _ |a Scharfenberg, Daniel
|b 3
700 1 _ |a Kufer, Konstantin
|0 P:(DE-2719)9003179
|b 4
|u dzne
700 1 _ |a Farrher, Ezequiel
|b 5
700 1 _ |a Fink, Gereon R
|b 6
700 1 _ |a Sommerauer, Michael
|0 P:(DE-2719)9003277
|b 7
|u dzne
700 1 _ |a Kalbe, Elke
|b 8
773 _ _ |a 10.1038/s41531-025-01161-2
|g Vol. 11, no. 1, p. 287
|0 PERI:(DE-600)2819218-7
|n 1
|p 287
|t npj Parkinson's Disease
|v 11
|y 2025
|x 2373-8057
856 4 _ |u https://pub.dzne.de/record/281634/files/DZNE-2025-01157%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281634/files/DZNE-2025-01157.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/281634/files/DZNE-2025-01157%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281634/files/DZNE-2025-01157.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281634
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9003179
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9003277
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:43:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:43:48Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:43:48Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1011302
|k AG Wüllner
|l Biomarker Parkinson's Disease
|x 0
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold
|l Vascular Neurology
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011302
980 _ _ |a I:(DE-2719)1013020
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21